Compare FNGR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNGR | SCYX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 51.1M |
| IPO Year | 2014 | 2014 |
| Metric | FNGR | SCYX |
|---|---|---|
| Price | $0.16 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 3.0M | 242.8K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,132,261.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.57 |
| 52 Week High | $2.20 | $5.62 |
| Indicator | FNGR | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 29.39 | 62.00 |
| Support Level | N/A | $4.65 |
| Resistance Level | $0.37 | $5.56 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 2.52 | 73.86 |
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company's business line includes Telecommunications Products and Services, Value Added Products and Services, Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.